Market Trends of Canine Atopic Dermatitis Industry
Monoclonal Antibody Segment Expected to Exhibit Significant Market Growth Over the Forecast Period
The monoclonal antibodies segment is expected to exhibit high market growth over the forecast period. The major attributable factors are the rising awareness of biotherapeutics and increasing product approvals. Moreover, the rising dog adoption around the world is also a major factor driving the segment growth. For instance, according to the data published by the European Pet Food Industry: Facts and Figures 2021 report in 2022, 12,000,000 dogs were reported in the United Kingdom in 2021. Also, as per the same source, the estimated percentage of United Kingdom households owning at least one dog was 27% in 2021. This shows that the adoption of dogs was significantly high in the country.
Moreover, according to the data published by the European Pet Food Industry: Facts and Figures 2021 report in 2022, 12,000,000 dogs were reported in the United Kingdom in 2021. Also, as per the same source, the estimated percentage of United Kingdom households owning at least one dog was 27% in 2021. This shows that the adoption of dogs was significantly high in the country.
Similarly, according to Der Deutsche Heimtiermarktdata updated in 2022, 47% of the households in Germany had pets in 2021, and 34.7 million dogs, cats, small animals, and ornamental birds were kept by the population as pets. Also, as per the same source, 10.3 million dogs lived in 21% of households in Germany in 2021. Thus, the rising dog adoption is also expected to boost segment growth.
Furthermore, according to an article published by Frontiers in July 2022, Cytopoint, a caninized monoclonal anti-IL-31 antibody, was found to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis, as a recent retrospective study reported that Cytopoint achieved treatment success in 87.8% of the cases with allergic dermatitis. Thus, the increasing success of various monoclonal antibodies for the treatment of atopic dermatitis in dogs is expected to boost segment growth.
Thus, the aforementioned factors such as the rising dog adoption and the increasing efficacy of monoclonal antibodies in the treatment of atopic dermatitis in dogs are expected to boost the segment growth.
North America Expected to Hold Significant Market Share During the Forecast Period
North America is expected to be a significant region for the canine atopic dermatitis market owing to increased spending in R&D activities, the high concentration of key market players, and the high rate of households with dog ownership in the region.
For instance, according to the data from the Canadian Animal Health Institute (CAHI) in September 2022, it is estimated that more than half of Canadian households (60%) own at least one dog or cat in 2022. The data also detailed that the dog population increased to 7.9 million in 2022. Thus, with a large population base of dogs, the burden of atopic dermatitis among the canine population is expected to be higher which is anticipated to drive the growth in the studied market.
In the North American region, the United States is expected to hold a significant share in the studied market as the United States has one of the highest numbers of dogs in the region coupled with high animal health expenditure and a high burden of canine atopic dermatitis cases. For instance, according to the 2021-2022 American Pet Product Association (APPA) National Pet Owners Survey, about 70% of the United States households owned a pet which is about 90.5 million homes, and dogs were among the major pets with a total population of 69 million. Further, as per the same source, pet owners spent about USD 458 for dogs for surgical vet visits, and for a routine vet, they spent USD 242 for dogs. This data shows the presence of a large dog population in the country and spending on them which is usually high as compared to other regions.
Moreover, the developments by key market players are also expected to increase the market growth. For instance, in July 2021, Virbac Corporation announced the availability of CYCLAVANCE (cyclosporine oral solution) USP MODIFIED, an oral solution for the control of atopic dermatitis in dogs in the United States.
Hence, the aforementioned factors such as the growing dog adoption, and the increasing developments by key market players are expected to boost the market growth in the region.
